# Helen Sabzevari

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/helen-sabzevari
Canonical HTML page: https://gethealthbrief.com/entity/helen-sabzevari

## Timeline

- **2026-03-24**: Paysign 2026 Outlook — Paysign projects 30-35% revenue growth for the coming fiscal year.
- **2026-01-15**: Recombinant Albumin Launch — Dyadic and ProLiant initiate commercial launch of recombinant albumin.
- **2025-12-31**: Dyadic Year-End Cash — Dyadic ends fiscal year with $8.6 million in cash and liquid assets.
- **2025-11-01**: Precigen Commercial Launch — Initial commercial shipments of Papzimius for adult RRP begin.

## Recent coverage (1 stories)

### Biotech Commercialization Pivot: Dyadic and Precigen Scale Post-R&D
2026-03-26 00:19:20 · Sentiment: Positive · Impact: 6/10 · Sources: 5

The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.
Full story: https://gethealthbrief.com/story/biotech-commercialization-pivot-dyadic-precigen-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.